Pure scientists corresponding to physicists pioneered the sharing of computing sources, which led to the creation of the Grid. The inter area switch technique of this know-how has hitherto been an intuitive course of with out in depth evaluation. Some difficulties going through the life science neighborhood on this switch might be understood utilizing the Bozeman’s “Effectiveness Mannequin of Know-how Switch”. Bozeman’s and classical know-how switch approaches take care of applied sciences which have achieved sure stability.
Grid and Cloud options are applied sciences, that are nonetheless in flux. We present how Grid computing creates new difficulties within the switch course of that aren’t thought of in Bozeman’s mannequin. We present why the success of healthgrids needs to be measured by the certified scientific human capital and the alternatives created, and never primarily by the market affect.
We conclude with suggestions that may assist enhance the adoption of Grid and Cloud options into the biomedical neighborhood. These outcomes give a extra concise clarification of the difficulties many life science IT tasks are going through within the late funding durations, and present leveraging steps that may assist overcoming the “vale of tears”.
Biomedical alerts monitoring based mostly in cellular computing.
The primary goal of this mission consists within the improvement of a biomedical instrumentation prototype for acquisition, processing and transmission of biomedical alerts. These biomedical alerts are acquired after which processed with a microcontroller. After processing, all knowledge are despatched to a communication interface that may ship this data to a private laptop or a cellular phone.
The prototype developed, which is a digital blood stress meter, is meant to permit distant monitoring of sufferers dwelling in areas with restricted entry to medical help or scarce medical sources. We consider that this improvement could possibly be useful to enhance folks’s high quality of life, in addition to to permit an enchancment within the authorities attendance indices.
Cloud computing: a brand new enterprise paradigm for biomedical data sharing.
We study how the biomedical informatics (BMI) neighborhood, particularly consortia that share knowledge and functions, can benefit from a brand new useful resource referred to as “cloud computing”. Clouds typically provide sources on demand. In most clouds, expenses are pay per use, based mostly on giant farms of cheap, devoted servers, typically supporting parallel computing. Substantial economies of scale doubtlessly yield prices a lot decrease than devoted laboratory techniques and even institutional knowledge facilities.
General, even with conservative assumptions, for functions that aren’t I/O intensive and don’t demand a totally mature atmosphere, the numbers prompt that clouds can typically present main enhancements, and needs to be significantly thought of for BMI. Methodologically, it was very advantageous to formulate analyses when it comes to element applied sciences; specializing in these specifics enabled us to bypass the cacophony of other definitions (e.g., precisely what does a cloud embrace) and to investigate alternate options that make use of among the element applied sciences (e.g., an establishment’s knowledge middle).
Relative analyses had been one other nice simplifier. Quite than itemizing absolutely the strengths and weaknesses of cloud-based techniques (e.g., for safety or knowledge preservation), we deal with the modifications from a selected place to begin, e.g., particular person lab techniques. We regularly discover a tough parity (in precept), however one wants to look at particular person acquisitions–is a loosely managed lab transferring to a nicely managed cloud, or a tightly managed hospital knowledge middle transferring to a poorly safeguarded cloud?
Multidimensional AM-FM fashions and strategies for biomedical picture computing.
This paper supplies an summary of multidimensional AM-FM strategies for analyzing medical pictures and movies. During the last decade, a number of new AM-FM demodulation strategies have been developed. We offer a dialogue of what many of those strategies share in widespread, and provides some particulars on current, Hilbert-based approaches.
Medical picture functions vary from medical picture segmentation, decision enhancement, classification, reconstruction to new strategies for video movement estimation. A short abstract of options for future work on this space can also be given.
Ahead-calculated analytical interferograms in pass-through photon-based biomedical transillumination.
Lately, we’ve got launched a transillumination approach for biomedical analysis. The approach, pass-through photon-based transillumination, depends on interferometric measurements to recuperate the knowledge of curiosity. On this work, we current the forward-calculated analytical interferograms that describe the habits of the system. Stochastic modeling of radiation interacting with tissue permits dedication of amplitude and part parameters, indispensable for computation of the interferograms.
) Anti-LAMP3 antibody (Alexa-fluor 647) |
|||
| STJ170006 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
) Anti-IL3RA antibody (Alexa-fluor 488) |
|||
| STJ170009 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
) Anti-IL3RA antibody (Alexa-fluor 546) |
|||
| STJ170010 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
) Anti-IL3RA antibody (Alexa-fluor 647) |
|||
| STJ170011 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
) Anti-CD207 antibody (Alexa-fluor 488) |
|||
| STJ170014 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
) Anti-CD207 antibody (Alexa-fluor 546) |
|||
| STJ170015 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
) Anti-CD207 antibody (Alexa-fluor 647) |
|||
| STJ170016 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
) Anti-IL7R antibody (Alexa-fluor 488) |
|||
| STJ170020 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
) Anti-IL7R antibody (Alexa-fluor 546) |
|||
| STJ170021 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
) Anti-IL7R antibody (Alexa-fluor 647) |
|||
| STJ170022 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
) Goat anti Mouse IgG1 (Alexa Fluor 488) |
|||
| 43R-1649 | Fitzgerald | 500 ug | EUR 570 |
|
Description: Goat anti Mouse IgG1 secondary antibody (Alexa Fluor 488) |
|||
 Anti-Hu CD16 Alexa Fluor® 488 |
|||
| A4-646-T100 | ExBio | 100 tests | EUR 269 |
 Alpha Fluor™ 532 acid [equivalent to Alexa Fluor™ 532 acid] |
|||
| 1795 | AAT Bioquest | 10 mg | EUR 393 |
) Mouse IgG1-Alexa 555 conjugate (isotype control) |
|||
| 20102-101-A555 | Alpha Diagnostics | 50 Tests | EUR 263 |
 AF350 Phalloidin [equivalent to Alexa Fluor® 350 phalloidin] |
|||
| 23150 | AAT Bioquest | 300 Tests | EUR 306 |
 AF488 Phalloidin [equivalent to Alexa Fluor® 488 phalloidin] |
|||
| 23153 | AAT Bioquest | 300 Tests | EUR 306 |
 AF594 Phalloidin [equivalent to Alexa Fluor® 594 phalloidin] |
|||
| 23158 | AAT Bioquest | 300 Tests | EUR 306 |
 AF350-streptavidin conjugate [Streptavidin, Alexa Fluor™ 350 Conjugate] |
|||
| 16890 | AAT Bioquest | 1 mg | EUR 176 |
 AF488-streptavidin conjugate [Streptavidin, Alexa Fluor™ 488 Conjugate] |
|||
| 16891 | AAT Bioquest | 1 mg | EUR 176 |
 AF594-streptavidin conjugate [Streptavidin, Alexa Fluor™ 594 Conjugate] |
|||
| 16892 | AAT Bioquest | 1 mg | EUR 176 |
 (Alexa Fluor 594)) Donkey anti Goat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID005AF | Fitzgerald | 500 ug | EUR 338 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
 (Alexa Fluor 594)) Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID022AF | Fitzgerald | 500 ug | EUR 364 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
 (Alexa Fluor 647)) Donkey anti Goat IgG (H + L) (Alexa Fluor 647) |
|||
| 43R-ID028AF | Fitzgerald | 500 ug | EUR 430 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 647) |
|||
Donkey anti Rat IgG (H + L) (Alexa Fluor 594) |
|||
| 43R-ID047AF | Fitzgerald | 500 ug | EUR 462 |
|
Description: Donkey anti Rat IgG (H + L) secondary antibody (Alexa Fluor 594) |
|||
 (Alexa Fluor 594)) Donkey anti Chicken IgY (H + L) (Alexa Fluor 594) |
|||
| 43R-ID056AF | Fitzgerald | 500 ug | EUR 343 |
|
Description: Donkey anti Chicken IgY secondary antibody (H + L) (Alexa Fluor 594) |
|||
 (Alexa Fluor 647)) Donkey anti Chicken IgY (H + L) (Alexa Fluor 647) |
|||
| 43R-ID060AF | Fitzgerald | 300 ug | EUR 425 |
|
Description: Donkey anti Chicken IgY (H + L) (Fab'2) (Alexa Fluor 647) |
|||
 (Alexa Fluor 594)) Rabbit anti Chicken IgY (H + L) (Alexa Fluor 594) |
|||
| 43R-IR016AF | Fitzgerald | 1 mg | EUR 281 |
|
Description: Rabbit anti Chicken IgY (H + L) secondary antibody (Alexa Fluor 594) |
|||
 Anti-Hu CD72 Alexa Fluor® 488 |
|||
| A4-310-T100 | ExBio | 100 tests | EUR 269 |
 Anti-Bov CD9 Alexa Fluor® 488 |
|||
| A4-354-C100 | ExBio | 0.1 mg | EUR 269 |
 Anti-Hu CD30 Alexa Fluor® 700 |
|||
| A7-455-T100 | ExBio | 100 tests | EUR 269 |
 Anti-Hu CD94 Alexa Fluor® 700 |
|||
| A7-727-T100 | ExBio | 100 tests | EUR 269 |
 Anti-Hu CD56 Alexa Fluor® 700 |
|||
| A7-789-T100 | ExBio | 100 tests | EUR 269 |
 Alexa Fluor 594–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 594–conjugated |
|||
| S0005 | Affbiotech | 200ul | EUR 376 |
 Alexa Fluor 594–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 594–conjugated |
|||
| S0006 | Affbiotech | 200ul | EUR 376 |
 Alexa Fluor 647–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 647–conjugated |
|||
| S0013 | Affbiotech | 200ul | EUR 304 |
 Alexa Fluor 647–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 647–conjugated |
|||
| S0014 | Affbiotech | 200ul | EUR 304 |
 Alexa Fluor 488–conjugated) Goat Anti-Mouse IgG(H+L) Alexa Fluor 488–conjugated |
|||
| S0017 | Affbiotech | 200ul | EUR 304 |
 Alexa Fluor 488–conjugated) Goat Anti-Rabbit IgG(H+L) Alexa Fluor 488–conjugated |
|||
| S0018 | Affbiotech | 200ul | EUR 304 |
 (Fab 2) (Alexa Fluor 594)) Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
|||
| 43R-ID012AF | Fitzgerald | 300 ug | EUR 410 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
|||
, Alexa Fluor® 594 Conjugated) Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated |
|||
| Ab8011-001 | GenDepot | 1mg | EUR 334 |
, Alexa Fluor® 488 Conjugated) Donkey Anti-Rabbit IgG (H+L), Alexa Fluor® 488 Conjugated |
|||
| Ab8032-001 | GenDepot | 0.5mg | EUR 435 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY153) Alexa Fluor® 488 |
|||
| A4-686-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY72) Alexa Fluor® 488 |
|||
| A4-712-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY142) Alexa Fluor® 488 |
|||
| A4-730-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 488) Anti-Hu CD3 zeta (pY111) Alexa Fluor® 488 |
|||
| A4-737-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY153) Alexa Fluor® 647 |
|||
| A6-686-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY72) Alexa Fluor® 647 |
|||
| A6-712-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY142) Alexa Fluor® 647 |
|||
| A6-730-C100 | ExBio | 0.1 mg | EUR 269 |
 Alexa Fluor<sup>®</sup> 647) Anti-Hu CD3 zeta (pY111) Alexa Fluor® 647 |
|||
| A6-737-C100 | ExBio | 0.1 mg | EUR 269 |
 Monoclonal Antibody (104G4) (Alexa Fluor<sup>®</sup> 488)) Anti-LAMP3 (human) Monoclonal Antibody (104G4) (Alexa Fluor® 488) |
|||
| M09406 | BosterBio | 100ug | EUR 565 |
|
Description: Mouse Monoclonal LAMP3 (human) Antibody (104G4) (Alexa Fluor® 488). Validated in IHC and tested in Human. |
|||
 Monoclonal Antibody (DCGM4/122D5) (Alexa Fluor<sup>®</sup> 488)) Anti-Langerin (human) Monoclonal Antibody (DCGM4/122D5) (Alexa Fluor® 488) |
|||
| M02316 | BosterBio | 100ug | EUR 580 |
|
Description: Mouse Monoclonal Langerin (human) Antibody (DCGM4/122D5) (Alexa Fluor® 488). Validated in IHC and tested in Human. |
|||
-Alexa 488 Fluor conjugate (adsorbed with human IgG)) Rabbit Anti-Rat IgG (H+L)-Alexa 488 Fluor conjugate (adsorbed with human IgG) |
|||
| 50336 | Alpha Diagnostics | 0.5 ml | EUR 225 |
-Alexa 594 Fluor conjugate (adsorbed with human IgG)) Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
|||
| 50337 | Alpha Diagnostics | 0.5 ml | EUR 225 |
 AG 555 |
|||
| B6377-10 | ApexBio | 10 mg | EUR 144 |
|
Description: AG 555 is a potent and selective inhibitor of EGFR with IC50 value of 0.7 ?M. The epidermal growth factor receptor (EGFR) is the cell-surface receptor for epidermal growth factor and plays an important role in tumor invasion and cancer cell proliferation. |
|||
AG 555 |
|||
| B6377-25 | ApexBio | 25 mg | EUR 276 |
|
Description: AG 555 is a potent and selective inhibitor of EGFR with IC50 value of 0.7 ?M. The epidermal growth factor receptor (EGFR) is the cell-surface receptor for epidermal growth factor and plays an important role in tumor invasion and cancer cell proliferation. |
|||
AG 555 |
|||
| B6377-50 | ApexBio | 50 mg | EUR 447 |
|
Description: AG 555 is a potent and selective inhibitor of EGFR with IC50 value of 0.7 ?M. The epidermal growth factor receptor (EGFR) is the cell-surface receptor for epidermal growth factor and plays an important role in tumor invasion and cancer cell proliferation. |
|||
 MCC-555 |
|||
| C4892-1 | ApexBio | 1 mg | EUR 158 |
|
Description: MCC-555, also known as RWJ-241947, is a novel peroxisome proliferator?activated receptor ? ligand [1]. The PPAR? receptors mainly express in adipose tissue, colon and macrophages involved in regulating fatty acid storage and glucose metabolism. |
|||
MCC-555 |
|||
| C4892-10 | ApexBio | 10 mg | EUR 918 |
|
Description: MCC-555, also known as RWJ-241947, is a novel peroxisome proliferator?activated receptor ? ligand [1]. The PPAR? receptors mainly express in adipose tissue, colon and macrophages involved in regulating fatty acid storage and glucose metabolism. |
|||
MCC-555 |
|||
| C4892-5 | ApexBio | 5 mg | EUR 538 |
|
Description: MCC-555, also known as RWJ-241947, is a novel peroxisome proliferator?activated receptor ? ligand [1]. The PPAR? receptors mainly express in adipose tissue, colon and macrophages involved in regulating fatty acid storage and glucose metabolism. |
|||
AG 555 |
|||
| HY-15336 | MedChemExpress | 10mM/1mL | EUR 126 |
 HIV-1 pol Integrase) Recombinant (E.Coli, His-tag) HIV-1 pol Integrase |
|||
| RP-555 | Alpha Diagnostics | 10 ug | EUR 164 |
 Alpha Fluor™ 488 amine |
|||
| 1705 | AAT Bioquest | 1 mg | EUR 306 |
 Alpha Fluor™ 488 Hydroxylamine |
|||
| 1900 | AAT Bioquest | 1 mg | EUR 306 |
 Tide Fluor 2-LL-37 |
|||
| H-8286.0100 | Bachem | 0.1mg | EUR 312 |
|
Description: Sum Formula: C205H340N60O53+dye |
|||
Tide Fluor 2-LL-37 |
|||
| H-8286.0500 | Bachem | 0.5mg | EUR 1017 |
|
Description: Sum Formula: C205H340N60O53+dye |
|||
 Anti-Cytokeratins Alexa Fluor488 |
|||
| A4-108-C025 | ExBio | 0.025 mg | EUR 175 |
Anti-Cytokeratins Alexa Fluor488 |
|||
| A4-108-C100 | ExBio | 0.1 mg | EUR 310 |
 Anti-PSMA Alexa Fluor488 |
|||
| A4-539-C025 | ExBio | 0.025 mg | EUR 227 |
Anti-PSMA Alexa Fluor488 |
|||
| A4-539-C100 | ExBio | 0.1 mg | EUR 414 |
 Anti-FoxP3 Alexa Fluor488 |
|||
| A4-601-C025 | ExBio | 0.025 mg | EUR 201 |
Anti-FoxP3 Alexa Fluor488 |
|||
| A4-601-C100 | ExBio | 0.1 mg | EUR 362 |
 Anti-Phosphotyrosine Alexa Fluor647 |
|||
| A6-263-C025 | ExBio | 0.025 mg | EUR 154 |
Anti-Phosphotyrosine Alexa Fluor647 |
|||
| A6-263-C100 | ExBio | 0.1 mg | EUR 269 |
 Anti-LCK Alexa Fluor647 |
|||
| A6-269-C025 | ExBio | 0.025 mg | EUR 206 |
Anti-LCK Alexa Fluor647 |
|||
| A6-269-C100 | ExBio | 0.1 mg | EUR 373 |
 Anti-FoxP3 Alexa Fluor647 |
|||
| A6-601-C025 | ExBio | 0.025 mg | EUR 201 |
Anti-FoxP3 Alexa Fluor647 |
|||
| A6-601-C100 | ExBio | 0.1 mg | EUR 362 |
 CellBrite Fix 555 |
|||
| 30088 | Biotium | 1KIT | EUR 563 |
|
Description: Minimum order quantity: 1 unit of 1KIT |
|||
 Cyanine 555 aminooxy |
|||
| 96009 | Biotium | 1MG | EUR 342 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
 Cyanine 555 tyramide |
|||
| 96020 | Biotium | 0.5mg | EUR 353 |
|
Description: Minimum order quantity: 1 unit of 0.5mg |
|||
 Cyanine 555 alkyne |
|||
| 92100 | Biotium | 1MG | EUR 226 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
) Monoclonal Anti-Monkey IgG-Alexa 555 Conj. (specific for monkey; no reactivity with human or animals IgG) |
|||
| 70030-AF555 | Alpha Diagnostics | 50 tests | EUR 347 |
 Metal Fluor™ Zn-520, AM |
|||
| 21263 | AAT Bioquest | 1 mg | EUR 219 |
 Alpha Fluor™ 488 NHS Ester |
|||
| 1812 | AAT Bioquest | 1 mg | EUR 219 |
 Alpha Fluor™ 532 NHS Ester |
|||
| 1819 | AAT Bioquest | 1 mg | EUR 219 |
 Alpha Fluor™ 594 C5 Maleimide |
|||
| 1891 | AAT Bioquest | 1 mg | EUR 219 |
 Helix Fluor™ 6-JOE Phosphoramidite |
|||
| 6046 | AAT Bioquest | 100 umoles | EUR 50 |
) Tide Fluor 2-LL-37 (scrambled) |
|||
| H-8288.0100 | Bachem | 0.1mg | EUR 312 |
|
Description: Sum Formula: C205H340N60O53+dye |
|||
Tide Fluor 2-LL-37 (scrambled) |
|||
| H-8288.0500 | Bachem | 0.5mg | EUR 1017 |
|
Description: Sum Formula: C205H340N60O53+dye |
|||
 Tide Fluor 5WS-o-Conotoxin GVIA |
|||
| H-8356.0100 | Bachem | 0.1mg | EUR 1146 |
|
Description: Sum Formula: C120H182N38O43S6+dye |
|||
 conjugate) Streptavidin-Alexa488 (Alexas fluor 488) conjugate |
|||
| SV-A488-100 | Alpha Diagnostics | 100 tests | EUR 225 |
 conjugate) Streptavidin-Alexa594 (Alexas fluor 594) conjugate |
|||
| SV-A594-100 | Alpha Diagnostics | 100 tests | EUR 225 |
Pattern variability is assessed by learning tissue phantoms much like these used within the experimental verification of the approach and which can be consultant of (irregular) dental tissues. For tissue characterization, good restoration of the built-in attenuation ensues by using spatially compact radiation sources. For tissue imaging, spatially prolonged sources with broad bandwidth are superior because of the implicit longitudinal coherence filter. For each functions, pattern variability points could also be neutralized by allowing spatial divergence of scattered photons.